evoke and evoke+: Two phase 3 randomised placebo-controlled trials of semaglutide in participants with early-stage Alzheimer’s disease (NCT04777396 and NCT04777409)

Disease Areas
Congresses
Scientific Publications
IME

Search Science Hub

Register Login

My Account

Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

Congresses
CTAD 2025
evoke and evoke+: Two phase 3 randomised placebo-controlled trials of semaglutide in participants with early-stage Alzheimer’s disease (NCT04777396 and NCT04777409)